Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565214 | 0.86 | SLC6A3 (0.69) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1565823 | 0.85 | SLC6A3 (0.70) | SLC6A3SLC6A2SLC6A4LMNA | |
| SCHEMBL4627138 | 0.83 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17846874 | 0.82 | SLC6A3 (0.44) | SLC6A3MEN1LMNAALOX12HTT | |
| SCHEMBL17846902 | 0.82 | SLC6A3 (0.41) | SLC6A3MEN1LMNAHTTKMT2A | |
| SCHEMBL17846913 | 0.79 | SLC6A3 (0.38) | SLC6A3MEN1LMNAHTTKMT2A | |
| SCHEMBL1565129 | 0.79 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4HPGDSMN1; SMN2 | |
| SCHEMBL17846888 | 0.78 | HTR1E (0.47) | MEN1LMNAKMT2A | |
| SCHEMBL1564941 | 0.78 | HTR1E (0.47) | MEN1LMNAKMT2A | |
| SCHEMBL1565904 | 0.78 | MEN1 (0.47) | SLC6A3SLC6A2SLC6A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | US | disclosed |
| EP-3233802-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097013-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097013-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | PTGER1, PTGES, PTGES3 | SLC6A3 3690/4885SLC6A2 4448/4885SLC6A4 3749/4885 |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | PTGER1, PTGES, PTGES3 | SLC6A3 3690/4885SLC6A2 4448/4885SLC6A4 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.